- Home
- SNTI vs CNVS Comparison
SNTI vs CNVS Comparison
Compare SNTI & CNVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- CNVS
- Stock Information
- Founded
- SNTI 2016
- CNVS 2000
- Country
- SNTI United States
- CNVS United States
- Employees
- SNTI N/A
- CNVS N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- CNVS Consumer Electronics/Video Chains
- Sector
- SNTI Health Care
- CNVS Consumer Discretionary
- Exchange
- SNTI Nasdaq
- CNVS Nasdaq
- Market Cap
- SNTI 85.3M
- CNVS N/A
- IPO Year
- SNTI N/A
- CNVS 2003
- Fundamental
- Price
- SNTI $2.26
- CNVS $6.04
- Analyst Decision
- SNTI Strong Buy
- CNVS Buy
- Analyst Count
- SNTI 2
- CNVS 1
- Target Price
- SNTI $8.50
- CNVS $10.00
- AVG Volume (30 Days)
- SNTI 385.8K
- CNVS 373.4K
- Earning Date
- SNTI 08-12-2025
- CNVS 08-13-2025
- Dividend Yield
- SNTI N/A
- CNVS N/A
- EPS Growth
- SNTI N/A
- CNVS N/A
- EPS
- SNTI N/A
- CNVS 0.16
- Revenue
- SNTI N/A
- CNVS $78,181,000.00
- Revenue This Year
- SNTI N/A
- CNVS N/A
- Revenue Next Year
- SNTI $150.00
- CNVS N/A
- P/E Ratio
- SNTI N/A
- CNVS $37.75
- Revenue Growth
- SNTI N/A
- CNVS 59.13
- 52 Week Low
- SNTI $1.52
- CNVS $0.72
- 52 Week High
- SNTI $16.94
- CNVS $6.24
- Technical
- Relative Strength Index (RSI)
- SNTI 37.88
- CNVS 89.80
- Support Level
- SNTI $2.05
- CNVS $3.72
- Resistance Level
- SNTI $2.35
- CNVS $5.31
- Average True Range (ATR)
- SNTI 0.30
- CNVS 0.36
- MACD
- SNTI 0.00
- CNVS 0.19
- Stochastic Oscillator
- SNTI 20.00
- CNVS 92.06
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.